HTTIF (HighTide Therapeutics) Short-Term Debt: $4.61 Mil (As of Dec. 2025)


HTTIF HighTide Therapeutics Inc HTTIF
14 GF Score
Price $0.39
! 3 Warning Signs
View Full Analysis

What is HighTide Therapeutics Short-Term Debt?

HighTide Therapeutics HTTIF 14 Short-Term Debt is $4.61 Mil as of Dec. 2025. GuruFocus rates HTTIF with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

HighTide Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2025 was $4.61 Mil.

HighTide Therapeutics's quarterly Short-Term Debt increased from Dec. 2024 ($6.45 Mil) to Jun. 2025 ($11.19 Mil) but then declined from Jun. 2025 ($11.19 Mil) to Dec. 2025 ($4.61 Mil).

HighTide Therapeutics's annual Short-Term Debt increased from Dec. 2023 ($0.49 Mil) to Dec. 2024 ($6.45 Mil) but then declined from Dec. 2024 ($6.45 Mil) to Dec. 2025 ($4.61 Mil).

HighTide Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

HighTide Therapeutics Short-Term Debt Related Terms

HighTide Therapeutics Short-Term Debt Historical Data

* Premium members only.

The historical data trend for HighTide Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

HighTide Therapeutics Short-Term Debt Chart

HighTide Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
1.10 1.17 0.49 6.45 4.61

HighTide Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Short-Term Debt Get a 7-Day Free Trial Premium Member Only 0.49 0.00 6.45 11.19 4.61
HTTIF
14GF Score
HighTide Therapeutics Inc HTTIF
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of $4.61 Mil mean?
HighTide Therapeutics (HTTIF) has a Short-Term Debt of $4.61 Mil as of Dec. 2025.
Is HighTide Therapeutics' Short-Term Debt too high?
HighTide Therapeutics' current Short-Term Debt is $4.61 Mil. Overall, HighTide Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does HighTide Therapeutics' Short-Term Debt compare to VRTX and REGN?
HighTide Therapeutics' Short-Term Debt of $4.61 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. HighTide Therapeutics's current Short-Term Debt is $4.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HighTide Therapeutics stock overvalued right now?
HighTide Therapeutics (HTTIF) has a current Short-Term Debt of $4.61 Mil. The current Short-Term Debt is $4.61 Mil. HighTide Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For HighTide Therapeutics (HTTIF), the current Short-Term Debt is $4.61 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

HighTide Therapeutics Business Description

Other Exchanges 02511:Hong Kong
Address Fubao Street, 9th to 10th Floor, Building D, Shenfang Park, Futian District, Shenzhen-Hong Kong Science and, Technology Innovation Cooperation Zone, Guangdong, Shenzhen, CHN, 518112
HighTide Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of first-in-class multifunctional, multi-targeted therapies for cardiovascular-kidney-metabolic (CKM) diseases and related metabolic disorders. The company is developing a pipeline of proprietary drug candidates targeting indications including type 2 diabetes mellitus, chronic kidney disease, obesity, metabolic dysfunction-associated steatohepatitis (MASH), and primary sclerosing cholangitis (PSC). Its core product candidate, HTD1801 (berberine ursodeoxycholate), is an orally delivered first-in-class anti-inflammatory metabolic modulator designed to target dual pathways involving AMPK activation and NLRP3 inflammasome inhibition.
14GF Score

Get the complete analysis for HTTIF

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.39
Price